TheraRadar
Clinical-Stage Companies / Sumitomo Pharma

Sumitomo Pharma

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 6/26/2024

22
Total Trials
10
Phase 3
4
Phase 2
0
Recruiting
218
Score

Pipeline by Phase

Phase 3
10
Phase 2
4
Phase 1
12

Therapeutic Focus

Schizophrenia Hepatocellular Carcinoma Influenza Levodopa-induced Dyskinesia Parkinson's Disease

Clinical Trials (22)

NCT05359081 Phase 3 TERMINATED

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

Started: 5/16/2022

NCT00711269 Phase 3 COMPLETED

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Started: 6/27/2008

NCT01986114 Phase 3 COMPLETED

A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

Started: 1/29/2014

NCT02287584 Phase 3 COMPLETED

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Started: 12/1/2014

NCT01614899 Phase 3 COMPLETED

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Started: 7/2/2012

NCT02335658 Phase 3 COMPLETED

Long-term Study of DSP-5423P in Patients With Schizophrenia

Started: 12/1/2014

NCT01986101 Phase 3 COMPLETED

A Phase III Study of SM-13496 in Patients With Bipolar I Depression.

Started: 2/19/2014

NCT01614912 Phase 3 COMPLETED

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

Started: 8/1/2012

NCT01207011 Phase 3 COMPLETED

Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer

Started: 10/1/2010

NCT04825860 Phase 2 TERMINATED

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Started: 3/29/2021

NCT06460064 Phase 1 COMPLETED

First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP

Started: 6/26/2024

NCT05435729 Phase 1 COMPLETED

A Pharmacodynamics and Safety Study of DSP-9632P in Patients With Levodopa-Induced Dyskinesia in Parkinson's Disease

Started: 5/31/2022

NCT02750891 Phase 1 COMPLETED

A Study of DSP-7888 in Pediatric Patients With Relapsed or Refractory High Grade Gliomas

Started: 4/1/2016

NCT03563560 Phase 1 COMPLETED

A Study of DSP-2033 (Alvocidib) in Patients With Acute Myeloid Leukemia

Started: 5/15/2018

NCT02347917 Phase 1 COMPLETED

A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma

Started: 2/1/2015

NCT02354898 Phase 1 COMPLETED

A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma

Started: 3/1/2015

NCT02436252 Phase 1 COMPLETED

Study of DSP-7888 in Patients With Myelodysplastic Syndrome

Started: 5/1/2015

NCT00925678 Phase 1 COMPLETED

DSP-3025 Study of Healthy Male Volunteers and Seasonal Allergic Rhinitis Male Patients Out of Season

Started: 6/1/2009

NCT03370640 Phase 1 COMPLETED

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

Started: 11/29/2017

NCT02358395 Phase 1 COMPLETED

A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma

Started: 2/1/2015

NCT04325737 Phase 1 COMPLETED

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

Started: 3/31/2020

NCT02641873 Phase 1 COMPLETED

A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer

Started: 12/1/2015

Drug Candidates

fH1 2 ug fH1 8 ug DSP-0546LP 2.5 ug DSP-0546LP 5 ug DSP-0546LP 10 ug Placebo SEP-363856 SEP-363856 50 mg SEP-363856 75 mg DSP-9632P 27.5 mg
Activity Status: Slowing
Last Trial Started: 6/26/2024
Last Trial Ended: 3/31/2026
Trials (12 months): 0
Completed Trials: 20
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.